NeuroOne Medical Technologies (NMTC) 10-K 20 Dec 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2019	Nov. 30, 2019	Mar. 29, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	NEUROONE MEDICAL TECHNOLOGIES Corp
Entity Central Index Key	0001500198
Amendment Flag	false
Document Type	10-K
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--09-30
Entity Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		13,697,373
Entity Public Float			$ 37,700,000
Entity File Number	000-54716
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Current assets:
Cash	$ 260,749	$ 13,260
Prepaid and other assets	41,002	5,378
Total current assets	301,751	18,638
Intangible assets, net	178,838	200,081
Property and equipment, net	52,026
Total assets	532,615	218,719
Current liabilities:
Accounts payable	1,152,472	221,235
Accrued expenses	617,721	1,591,022
Unsecured loans		283,000
Convertible promissory notes, net and accrued interest		1,393,804
Premium conversion derivatives		308,395
Total current liabilities	1,770,193	3,797,456
Warrant liability		817,155
Total liabilities	1,770,193	4,614,611
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2019 and 2018; no shares issued or outstanding as of September 30, 2019 and 2018.
Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2019 and 2018; 13,493,705 and 9,656,505 shares issued and outstanding as of September 30, 2019 and 2018, respectively.	13,494	9,657
Additional paid-in capital	15,987,799	6,052,161
Accumulated deficit	(17,238,871)	(10,457,710)
Total stockholders' deficit	(1,237,578)	(4,395,892)
Total liabilities and stockholders' deficit	$ 532,615	$ 218,719

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,493,705	9,656,505
Common stock, shares outstanding	13,493,705	9,656,505

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Operating expenses:
General and administrative	$ 2,676,872	$ 4,284,205
Research and development	715,086	1,529,189
Total operating expenses	3,391,958	5,813,394
Loss from operations	(3,391,958)	(5,813,394)
Interest expense	(763,065)	(284,557)
Net change in fair value for the warrant liability and premium conversion derivatives	336,596	(129,763)
Loss on note extinguishments	(1,314,487)	(553,447)
Net loss	$ (5,132,914)	$ (6,781,161)
Net loss per share:
Basic and diluted	$ (0.61)	$ (0.57)
Number of shares used in per share calculations:
Basic and diluted	8,420,529	11,857,571

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 7,865	$ 280,320	$ (5,324,796)	$ (5,036,611)
Balance, shares at Dec. 31, 2017	7,864,994
Issuance of common stock upon short term notes and convertible notes extinguishments	$ 1,147	2,348,790		2,349,937
Issuance of common stock upon short term notes and convertible notes extinguishments, shares	1,146,311
Issuance of warrants and warrant liability reclassification in connection with short-term notes and convertible notes extinguishments		2,008,796		2,008,796
Issuance of common stock under 2018 private placement	$ 445	824,449		824,894
Issuance of common stock under 2018 private placement, shares	445,200
Issuance of warrants under 2018 private placement		288,106		288,106
Issuance costs related to 2018 private placement		(173,067)		(173,067)
Issuance of common stock for consulting services	$ 200	469,300		469,500
Issuance of common stock for consulting services, shares	200,000
Stock-based compensation		5,467		$ 5,467
Exercise of stock options, shares
Net loss			(5,132,914)	$ (5,132,914)
Balance at Sep. 30, 2018	$ 9,657	6,052,161	(10,457,710)	(4,395,892)
Balance, shares at Sep. 30, 2018	9,656,505
Issuance of common stock upon conversion of convertible promissory notes	$ 839	1,920,881		1,921,720
Issuance of common stock upon conversion of convertible promissory notes, shares	839,179
Issuance of warrants and reclassification of warrant liability upon conversion of convertible promissory notes		1,565,402		1,565,402
Issuance of warrants under 2019 and 2018 private placements		1,709,233		1,709,233
Issuance costs related to 2019 and 2018 private placements		(1,168,679)		(1,168,679)
Issuance of warrants to brokers related to 2019 and 2018 private placements		378,838		378,838
Issuance of common stock for consulting services	$ 50	114,950		115,000
Issuance of common stock for consulting services, shares	50,000
Granting of options previously recorded as a liability		38,696		38,696
Stock-based compensation		324,205		324,205
Exercise of stock options	$ 198	52,313		$ 52,511
Exercise of stock options, shares	198,043			198,043
Issuance of stock awards	$ 11	24,990		$ 25,001
Issuance of stock awards, shares	10,503
Exercise of warrants	$ 231	416,102		416,333
Exercise of warrants, shares	231,296
Net loss			(6,781,161)	(6,781,161)
Balance at Sep. 30, 2019	$ 13,494	$ 15,987,799	$ (17,238,871)	$ (1,237,578)
Balance, shares at Sep. 30, 2019	13,493,705

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Operating activities
Net loss	$ (5,132,914)	$ (6,781,161)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	16,291	27,569
Stock-based compensation	486,120	491,749
Non-cash interest on convertible notes	152,045	51,333
Non-cash discount amortization on short-term notes and convertible notes	611,020	233,224
Revaluation of premium conversion derivatives	(371,831)	111,195
Revaluation of warrant liability	35,235	18,568
Loss on note extinguishments	1,314,487	553,447
Change in assets and liabilities:
Prepaid and other assets	1,768	(35,624)
Accounts payable and accrued expenses	658,572	(66,257)
Net cash used in operating activities	(2,229,207)	(5,395,957)
Investing activities
Purchase of intangible assets	(55,000)	(65,000)
Purchase of property and equipment		(58,352)
Net cash used in investing activities	(55,000)	(123,352)
Financing activities
Proceeds from issuance of convertible promissory notes	432,849
Proceeds from issuance of warrants associated with convertible notes	442,151
Proceeds from issuance of common stock in connection with private placement	824,894	4,561,215
Proceeds from issuance of warrants in connection with private placement	288,106	1,709,233
Issuance costs in connection with private placement		(689,494)
Exercise of warrants		416,333
Exercise of stock-options		52,511
Proceeds from unsecured loans	283,000	245,000
Repayment of unsecured loans		(528,000)
Net cash provided by financing activities	2,271,000	5,766,798
Net increase (decrease) in cash	(13,207)	247,489
Cash at beginning of period	26,467	13,260
Cash at end of period	13,260	260,749
Supplemental non-cash financing and investing transactions:
Conversion of short term notes and convertible promissory notes to equity	2,063,361	1,678,361
Exercise of premium conversion derivative liability		419,590
Reclassification of warrant liability to equity		835,723
Bifurcation of premium conversion derivative related to convertible notes	168,384
Issuance of additional warrants in connection with short-term notes and convertible promissory notes modifications	829,378
Change in accounts payable and accrued expenses attributed to private placement and convertible note issuance costs	175,917	100,347
Non-cash issuance of broker warrants in connection with private placements		378,838
Stock-based compensation liability reclassification to equity		$ 11,153

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 - Organization and Nature of Operations NeuroOne Medical Technologies Corporation (the "Company"), a Delaware Corporation, is an early-stage medical technology company developing comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson's disease, essential tremors, and other brain related disorders. To date, the Company has recorded no product sales and has a limited expense history. The Company is currently raising capital to fund the development of its proprietary technology and is seeking regulatory clearances required to initiate commercial activities.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2019
Going Concern [Abstract]
Going Concern	NOTE 2 - Going Concern The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and had an accumulated deficit of $17,238,871 as of September 30, 2019. The Company has not established a source of revenues to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company does not have adequate liquidity to fund its operations without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to continue to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology. Through September 30, 2019, the Company has completed a $528,000 unsecured loan financing, a $253,000 short-term promissory note financing (which notes were amended and restated to become convertible promissory notes), a $1,625,120 convertible promissory note financing of a planned $2.5 million subscription and a second $1,540,000 convertible promissory note financing of a planned $2 million subscription. All of the convertible notes were ultimately converted into common stock and warrants. In addition, the Company entered into two private placement transactions of its common stock and warrants beginning in July 2018 and December 2018, whereby $7.4 million in gross proceeds were raised out of a planned $11.8 million maximum offering under the subscription agreements for both private placements through September 30, 2019. The Company does not have adequate liquidity to fund its operations without raising additional funds. Management intends to continue to seek additional debt and/or equity financing to fund operations. However, if the Company is unable to raise additional funds, or the Company's anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company's operations. If management is unable to obtain the necessary capital, it may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 - Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America. In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company's fiscal year end from December 31 to September 30. The Company's fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018 ("the nine month transition period"). For comparative purposes, the transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Management's Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company's cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2019, the Company had $11,749 of deposits in excess of federally insured amounts. Common Stock Valuation As of September 30, 2019, the Company is utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company's common stock. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the "AICPA Valuation Framework"). The valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates. Prior to September 30, 2019, the Company estimated its enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies ("GPC") for calendar years 2019 through 2021 and on the sales price of the Company's common stock in recent private placement transactions (see Note 10 – Stockholders' Deficit). The resulting equity value from the GPC method portion was allocated to common stock using the option pricing method, and a discount for lack of marketability was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion that ranged from $2.05 to $2.52 per common share for the periods presented through June 30, 2019, the last date for which an evaluation was performed under the AICPA Valuation Framework. The fair value the Company's common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at a reporting date. Fair Value of Financial Instruments The Company's accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of September 30, 2019 and 2018, the fair values of cash, prepaids and other assets, accounts payable, accrued expenses and the unsecured loans, while outstanding, approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the convertible promissory notes of the Company, while outstanding, was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company, while outstanding, were based on both the estimated fair value of our common stock of $2.29 and $2.30 per share as of their conversion on February 28, 2019 and as of September 30, 2018, respectively, and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs. There were no transfers between fair value hierarchy levels during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018. The fair value of financial instruments measured on a recurring basis is as follows: As of September 30, 2018 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 817,155 $ — $ — $ 817,155 Premium conversion derivatives 308,395 — — 308,395 Total liabilities at fair value $ 1,125,550 $ — $ — $ 1,125,550 The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: 2019 2018 Warrant liability Balance as of beginning of period $ 817,155 $ 1,381,465 Value assigned to warrants in connection with convertible promissory and short-term notes — 579,873 Change in fair value of warrant liability 18,568 35,235 Reclassification to equity (835,723 ) (1,179,418 ) Balance as of end of period $ — $ 817,155 2019 2018 Premium debt conversion derivatives Balance as of beginning of period $ 308,395 $ 462,174 Value assigned to the underlying derivatives in connection with convertible promissory notes — 218,052 Change in fair value of premium debt conversion derivatives 111,195 (371,831 ) Reclassification to equity upon conversion of convertible promissory notes (419,590 ) — Balance as of end of period $ — $ 308,395 Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology. Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment ranges from three to five years and three years for software. Tangible assets acquired for research and development activities and have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company determined that no impairment triggers existed during the periods ended September 30, 2019 and 2018. Debt Issuance Costs Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations. Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials are offset against research and development expenses. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation Equity Warrant Liability The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7– Short-Term Promissory Notes and Unsecured Loans and Note 8 – Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders' (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations. Premium Debt Conversion Derivatives The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7– Short-Term Promissory Notes and Unsecured Loans and Note 8 – Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes. Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized. Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's convertible promissory notes, warrants and stock options and restricted stock units are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, restricted stock units and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the year ended September 30, 2019 or the nine month transition period ended September 30, 2018 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: 2019 2018 Warrants 7,265,598 2,927,572 (1) Stock options 845,840 368,216 Restricted stock units 31,515 — (1) As of September 30, 2018, there were additional potential warrants to be included which would be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future. Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company plans to adopt the standard on October 1, 2019, and will apply the modified retrospective approach to each lease in existence at the adoption date to the extent a lease is subject to this guidance. As such, the Company would not restate comparative periods and would recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company also plans to elect the package of practical expedients provided under the standard. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , Revenue from Contracts with Customers . In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement . ● Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ● Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee's assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. ● Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance on its financial statements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 4 - Commitments and Contingencies WARF License Agreement The Company has entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation ("WARF") for WARF's neural probe array and thin film micro electrode technology (the "WARF Agreement"). The Company is obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the WARF Agreement. Subject to earlier termination, the WARF Agreement otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The WARF Agreement is also subject to certain cancellation provisions with 90 days' notice should the Company elect not to continue to use the licensed technology. As of September 30, 2019, no royalty payments under the WARF Agreement were made or due to WARF. The Company has agreed to diligently develop, manufacture, market and sell products under the WARF Agreement in the United States during the term of the agreement and, specifically, that the Company would submit a business plan to WARF by February 1, 2018, which the Company submitted on January 18, 2018, and file an application for 510(k) marketing clearance with the FDA by February 1, 2019, which the Company submitted on a timely basis. WARF may terminate the WARF Agreement in the event that the Company fails to meet these milestones on 30 days' written notice, if the Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other covenant in the WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving the Company. WARF may also terminate this license (i) on 90 days' notice if the Company fails to have commercial sales of one or more FDA-approved products under the WARF Agreement by March 31, 2020 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters. Mayo Agreement The Company has an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research ("Mayo") related to certain intellectual property and development services for thin film micro electrode technology ("Mayo Agreement"). If the Company is successful in obtaining regulatory approval, the Company is to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the Mayo Agreement, set to expire May 25, 2037. Legal From time to time, the Company is subject to litigation and claims arising in the ordinary course of business. In May 2017, NeuroOne received a letter from PMT Corporation ("PMT"), the former employer of Mark Christianson and Wade Fredrickson. PMT claimed that these officers had breached their restrictive covenant obligations with PMT by virtue of their work for NeuroOne and such officer's prior work during employment with the prior employer, that these officers had breached their confidentiality and non-disclosure obligations to PMT and federal and state law by misappropriating confidential and trade secret information, and that the Company is responsible for tortious interference with contracts. The letter which purported to attach a noncompete agreement signed by Mr. Fredrickson demanded that Mr. Fredrickson (who resigned from the Company in June 2017), Mr. Christianson and NeuroOne cease and desist all competitive activities, that Mr. Fredrickson step down from his position and that Mr. Christianson and NeuroOne provide the former employer access to NeuroOne's systems to demonstrate that it is not using trade secrets or proprietary information nor competing with the former employer. On March 29, 2018, the Company was served with a complaint filed by PMT adding the Company, NeuroOne and Mr. Christianson to its existing lawsuit against Mr. Fredrickson in the Fourth Judicial District Court of the State of Minnesota. The complaint purported to attach Mr. Fredrickson's noncompete agreement as Exhibit A. In the lawsuit, PMT claims that Mr. Fredrickson and Mr. Christianson breached their non-competition, non-solicitation and non-disclosure obligations, breached their fiduciary duty obligations, were unjustly enriched, engaged in unfair competition, engaged in a civil conspiracy, tortiously interfered with PMT's contracts and prospective economic advantage, and breached a covenant of good faith and fair dealing. Against Mr. Fredrickson, PMT also alleges that he intentionally or negligently spoliated evidence, made negligent or fraudulent misrepresentations, misappropriated trade secrets in violation of Minnesota law, and committed the tort of conversion and statutory civil theft. Against the Company and NeuroOne, PMT alleges that the Company and NeuroOne were unjustly enriched and engaged in unfair competition. PMT asked the Court to impose a constructive trust over the shares held by Mr. Fredrickson and Mr. Christianson and to award compensatory damages, equitable relief, punitive damages, attorneys' fees, costs and interest. On April 18, 2018, Mr. Christianson, the Company and NeuroOne, Inc. filed a motion for dismissal, which was heard by the Court on October 11, 2018. The motion for dismissal states that: the contract claims against Mr. Christianson fail because his agreement was not supported by consideration; the Minnesota Uniform Trade Secrets Act preempts plaintiff's claims for unfair competition, civil conspiracy and unjust enrichment; plaintiff fails to state a claim regarding alleged breach of the duties of loyalty and good faith/fair dealing; plaintiff cannot legally obtain a constructive trust; plaintiff has insufficiently pled its tortious interference claims; and Plaintiff has not stated a claim for unfair competition. On January 7, 2019, the judge granted the motion for dismissal with respect to PMT's claim for breach of the duty of good faith and fair dealing, and denied the motion for dismissal with respect to the other claims presented. In April 2019, PMT served the Company, NeuroOne, Inc and Christianson with a proposed Second Amended Complaint which included new claims against the Company and NeuroOne, Inc for tortious interference with contract and tortious interference with prospective business advantage and punitive damages against the Company, NeuroOne Inc. and Christianson. On June 28, 2019 the Company presented evidence indicating that PMT had participated in a fraud on the Court, and sought an Order that PMT had waived the attorney client privilege. On July 16, 2019, Defendants served PMT with a joint notice of motion for sanctions seeking a variety of sanctions for litigation misconduct including, but not limited to, dismissal of the case and an award of attorneys' fees. The Company, NeuroOne Inc and Mr. Christianson further intend to move for summary judgment on all remaining claims asserted against them as well as for leave to assert counterclaims against PMT for abuse of process. On August 30, 2019, the Hennepin County District Court heard dispositive motions in this case. The district court judge indicated some claims would likely be tried to a jury and encouraged the parties to settle. On September 12, 2019, the district court heard NeuroOne's motion for sanctions. The district court has set the sanctions hearing for December 17, 2019 and December 18, 2019, and indicated any remaining claims would be tried in May 2020. NeuroOne and Mark Christianson (who has not worked for PMT since February 2012) intend to continue to defend themselves vigorously. Facility Lease The Company entered into a non-cancellable facility lease for its operations and headquarters for an eleven month term beginning on December 1, 2018. The monthly rent under the lease is $4,763. During the year ended September 30, 2019, rent expense associated with the facility lease amounted to $47,630. See Note 13 - Subsequent Events regarding a new facility lease that was executed in October 2019.

Intangibles and Property and Eq

Intangibles and Property and Equipment	12 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Property and Equipment	NOTE 5 – Intangibles and Property and Equipment Intangibles Intangible assets rollforward is as follows: Useful Life Net Intangibles, December 31, 2017 12-13 years $ 216,372 Less: amortization (16,291 ) Net Intangibles, September 30, 2018 200,081 Less: amortization (21,243 ) Net Intangibles, September 30, 2019 $ 178,838 The Company anticipates amortization expense of approximately $21,000 per year for fiscal year 2020 through 2024 based upon the two current license agreements. Property and Equipment Property and equipment held for use by category are presented in the following table: As of September 30, 2019 2018 Equipment $ 56,457 $ — Software 1,895 — Total property and equipment 58,352 — Less accumulated depreciation (6,326 ) — Property and equipment, net $ 52,026 $ — Depreciation expense was $6,326 and zero for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Accrued Expenses	NOTE 6 - Accrued Expenses Accrued expenses consisted of the following at September 30, 2019 and 2018: As of September 30, 2019 2018 License fees $ — $ 65,000 Legal services 228,709 833,470 Accrued issuance costs 50,400 204,000 Accrued payroll 171,087 276,639 Other 167,525 211,913 $ 617,721 $ 1,591,022 The "other" category is primarily comprised of board fees.

Short-Term Promissory Notes and

Short-Term Promissory Notes and Unsecured Loans	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Short-Term Promissory Notes and Unsecured Loans	NOTE 7 - Short-Term Promissory Notes and Unsecured Loans As of September 30, 2019 2018 Unsecured loans $ — $ 283,000 Unsecured Loans On May 17, 2018, the Company received cash proceeds of $168,000 from unsecured loans, represented by two promissory notes from a stockholder owning or affiliated with stockholders owning over 5% of the Company's common stock. The loans were interest free and required that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans included customary events of default provisions. The loans were fully repaid by June 30, 2019. On March 20, 2018, the Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from a stockholder owning over 5% of the Company's common stock. The loan was interest free and the Company repaid the principal in full in the second quarter of 2019 as required on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan included customary events of default provisions. In November 2018, the Company received cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from a stockholder owning or affiliated with stockholders owning over 5% of the Company's common stock. The loans were interest free and required that the Company repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or November 14, 2019. The loans were fully repaid by June 30, 2019. In December 2018, the Company received gross proceeds from an unsecured loan represented by one promissory note in the amount of $100,000 from a stockholder owning over 5% of the Company's common stock. The loan was interest free and required that the Company repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or December 12, 2019. The loan was fully repaid by June 30, 2019. Short-Term Promissory Notes The Company issued short-term unsecured and interest-free promissory notes (the "Short-Term Notes") for aggregate gross proceeds of $253,000 in August 2017 which included free standing equity warrants. The Short-Term Notes were subsequently amended in November 2017 and March 2018 to become convertible, extend the maturity date and include additional warrant coverage, new interest payment provisions and new conversion features described more fully below. Effective July 2, 2018, the Company entered into debt conversion agreements (the "Short-Term Note Conversion Agreements") with each Short-Term Note subscriber to (i) convert the outstanding principal and accrued and unpaid interest (the "Outstanding Balance") under the Short-Term Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "Short-Term Note Conversion Shares"); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. Interest on principal during the nine month transition period ended September 30, 2018 up through the July 2, 2018 conversion date was $6,296. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the "Short-Term Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The Short-Term Note Payment Warrants became exercisable commencing on July 2, 2018, and expire on November 21, 2021. Pursuant to the Short-Term Note Conversion Agreements, $259,297 of the outstanding principal and interest of the Short-Term Notes was converted into 144,053 shares of common stock with an additional 477,856 shares of common stock issuable upon exercise of the Replacement Warrants, Additional Warrants and Short-Term Payment Warrants. The conversion of the Short Term Notes was accounted for as an extinguishment. The difference in the carrying value of the Short-Term Notes coupled with the fair value of the underlying Replacement Warrants and Additional Warrants on the date of extinguishment relative to the higher fair value of the underlying common stock and collective Replacement Warrants, Additional Warrants and new Short-Term Payment Warrants issued was $148,787. The $148,787 differential was recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the nine month transition period ended September 30, 2018. The Replacement Warrants, Additional Warrants and Short-Term Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the July 2, 2018 Short-Term Note Conversion Agreements. All of the warrant terms became fixed and have identical provisions. Due to the previously granted warrants now having fixed terms, the warrant liability value of $148,052 was reclassified to equity. The warrants associated with the Short-Term Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Short-Term Warrants. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. Activity Prior to the July 2, 2018 Cancellation, Extinguishment and Conversion of the Short-Term Notes On November 30, 2017, the Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the "Original Warrants"). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment. The Short-Term Notes were subsequently amended and restated on March 12, 2018 (the "Amended and Restated Short-Term Notes"). The Amended and Restated Short-Term Notes became convertible promissory notes that had interest assessed at a fixed rate of 8% per annum and would have required the Company to repay the principal and accrued and unpaid interest thereon on the maturity date of July 31, 2018 (the "Short-Term Note Maturity Date"). Pursuant to the terms of each Amended and Restated Short-Term Note and a consent signed by the Company and each holder, the Original Warrants under the Short-Term Notes were modified whereby each subscriber received a replacement warrant (the "Replacement Warrants") upon the issuance of the Amended and Restated Short-Term Note, in lieu of the Original Warrant. In addition, each holder was issued an additional warrant (the "Additional Warrants"). Replacement Warrants Each Replacement Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the New Round Stock issued or issuable upon the conversion of the Amended and Restated Short-Term Note held by such holder at a per share exercise price equal to either (i) the actual per share price of New Round Stock if the Amended and Restated Short-Term Notes converted in connection with a Short-Term Note Qualified Financing or (ii) the price at which the Amended and Restated Short-Term Notes converted in connection with a change of control transaction. The Replacement Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Replacement Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein. The Replacement Warrants were deemed to be free-standing instruments and were accounted for as a liability given the variable number of shares issuable in connection with a possible change of control conversion event. The Company recorded an initial liability of $137,722 upon issuance with an increase to extinguishment loss described further below. The fair value changes of the warrant liability associated with the Amended and Restated Short-Term Notes were recorded at each reporting date in the consolidated statement of operations which amounted to an expense of $10,330 for the nine month transition period ended September 30, 2018. A Monte Carlo simulation model was used to estimate the aggregate fair value of the Replacement Warrants immediately prior to the July 2, 2018 Short-Term Note Conversion Agreement amendment. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 50 percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. Additional Warrants Each Additional Warrant issued on March 12, 2018 granted the holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80. The Additional Warrants were exercisable commencing on the Conversion Date and would have expired on November 21, 2021. The exercise price and number of the shares issuable upon exercising the Additional Warrants were subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein. The Additional Warrants were deemed to be free-standing instruments and were accounted for as equity as there were no variable terms. 189,750 shares of common stock were issuable upon exercise of the Additional Warrants as of the March 12, 2018 amendment date with terms that largely paralleled the provisions of the Original Warrants except that the Additional Warrants were exercisable on the Conversion Date as opposed to the Short-Term Note Maturity Date and the expiration date was moved up to November 21, 2021 from July 31, 2023. Premium Conversion Derivative Upon the March 2018 amendment, the Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share. The Company determined that the redemption feature under the Short-Term Notes qualified as an embedded derivative and was reflected as a liability in the amount of $49,668 at the time of the March 12, 2018 amendment with a corresponding offset to extinguishment loss which is described further below. Subsequent to the amendment, the embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Short-Term Notes in the consolidated statement of operations for a benefit of $(49,668) for the nine month transition period ended September 30, 2018. Other The March 2018 amendment resulted in a substantial modification to the Short-Term Notes whereby additional conversion features and warrant coverage were added. The Company recorded the Short-Term Note amendment under the provisions of extinguishment accounting. A loss on note extinguishments in the accompanying consolidated statement of operations for the nine month transition period ended September 30, 2018 was recorded in the amount of $186,220, which represented the difference between the carrying value of the Short-Term Notes and Original Warrants over the combined fair values of the Short-Term Notes, premium conversion derivative, Replacement Warrant and Additional Warrants on the date of the amendment. The fair value decrease of the Short-Term Notes (inclusive of principal and interest, non-bifurcated embedded conversion feature and the Additional Warrants) relative to its adjusted carrying value at the time of the amendment was $1,170 which was recorded as a reduction to additional paid-in capital on the accompanying consolidated balance sheet. As noted above, the Short-Term Notes were converted into shares of common stock and were not outstanding during the year ended September 30, 2019.

Convertible Promissory Notes an

Convertible Promissory Notes and Warrant Agreements	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Promissory Notes and Warrant Agreements	NOTE 8 - Convertible Promissory Notes and Warrant Agreements As of September 30, 2019 2018 2017 convertible promissory notes, net of discounts $ — $ 1,306,776 Accrued interest — 87,028 Total $ — $ 1,393,804 2016 Convertible Promissory Notes From November 2016 to June 2017, the Company issued convertible promissory notes (the "Convertible Notes") and common stock purchase warrants (the "Warrants") in an aggregate principal amount of $1,625,120 and entered into subscription agreements with subscribers (the "2016 Private Placement"). Effective July 2, 2018, however, the Company entered into debt conversion agreements (the "2016 Note Conversion Agreements") with each Convertible Note subscriber to (i) convert the Outstanding Balance under the Convertible Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "2016 Note Conversion Shares"); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the "2016 Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share. The 2016 Note Payment Warrants became exercisable commencing on July 2, 2018 and expire on November 21, 2021. Pursuant to the 2016 Note Conversion Agreements, $1,804,064 of the outstanding principal and interest of the 2016 Convertible Promissory Notes was converted into 1,002,258 shares of common stock and an additional 2,004,516 shares of common stock became issuable upon exercise of the Warrants and 2016 Note Payment Warrants. The conversion of the Convertible Notes was accounted for as an extinguishment. The difference in the carrying value of the Convertible Notes coupled with the fair value of the underlying Warrants upon conversion relative to the higher fair value of the underlying common stock and collective Warrants and new 2016 Note Payment Warrants issued was $979,480. The $979,480 differential total, inclusive of the unamortized discount remaining on the Convertible Notes of $11,143 as of July 2, 2018, was recorded as a loss on note extinguishments in the accompanying consolidated statement of operations during the nine month transition period ended September 30, 2018. The Warrants and 2016 Note Payment Warrants were deemed to be free-standing equity instruments upon execution of the 2016 Note Conversion Agreements. All of the warrant terms became fixed and the terms were identical. Due to the previously granted warrants now having fixed terms, the warrant liability value of $1,031,366 was reclassified to equity. The warrants associated with the Convertible Notes became immediately exercisable on July 2, 2018 and expire November 21, 2021. The Black-Scholes model was used to determine the July 2, 2018 fair value of the warrants associated with the Convertible Notes. Input assumptions used were as follows: a risk-free interest rate of 2.65 percent; expected volatility of 49.8% percent; expected life of 3.39 years; and expected dividend yield of 0 percent. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. During the nine month transition period ended September 30, 2018, interest on the principal was $65,727, and interest related to amortization of discounts related to the bifurcation of premium derivative liability, separation of warrants, revaluation discounts and issuance costs amounted to $70,324. The fair value changes related to the underlying premium conversion derivative amounted to a benefit of $(333,183) during the nine month transition period ended September 30, 2018. The fair value changes relating to the warrant liability amounted to a benefit of $(14,865) during the nine month transition period ended September 30, 2018. As noted above, the Convertible Notes were converted into shares of common stock and were not outstanding during the year ended September 30, 2019. 2017 Convertible Notes From October 2017 to May 2018, the Company issued convertible notes (the "2017 Convertible Notes") in an aggregate principal amount of $1,540,000 that bear interest at a fixed rate of 8% per annum and warrants to purchase shares of the Company's capital stock (the "New Warrants"). During the year ended September 30, 2019 and the nine month transition period end September 30, 2018, interest on the principal was $51,333 and $80,022, respectively. On February 28, 2019 following the 2017 Convertible Notes Qualified Financing (see below for definition), the outstanding principal and interest of $1,678,361 on the 2017 Convertible Notes were converted into 839,179 shares of common stock and 839,179 common stock purchase warrants with an exercise term of approximately 4.8 years and an exercise price $3.00 per share. The conversion was accounted for as a debt extinguishment given the bifurcation of the embedded premium debt conversion feature. The fair value of the newly issued common shares and warrants associated with the 2017 Convertible Notes conversion relative to the carrying value of the debt and fair value of warrant liability and premium derivative liability on the conversion date was $553,447 and was recorded as a loss on note extinguishments in the accompanying consolidated statements of operations for the year ended September 30, 2019. In addition, the previously issued New Warrants became immediately exercisable for 839,179 shares of common stock. Events Prior to the February 2019 Conversion On December 31, 2018, the 2017 Convertible Notes were amended to extend the maturity date from December 31, 2018 to June 30, 2019. The amendment was accounted for as a troubled debt restructuring given the Company's financial condition and given the concession granted by the lenders with regards to pushing out the maturity date to June 30, 2019 with no corresponding compensation paid for the extension. The future undiscounted cash flows of the 2017 Convertible Notes as amended exceeded their carrying value as of December 31, 2018. As such, no gain was recognized on December 31, 2018 and no adjustments were made to the 2017 Convertible Note carrying value. The 2017 Convertible Notes required the Company to repay the principal and accrued and unpaid interest thereon on June 30, 2019 (the "2017 Convertible Notes Maturity Date"). If the Company consummated an equity round of financing resulting in more than $3 million in gross proceeds before June 30, 2019 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The New Warrants would have also become exercisable upon a 2017 Convertible Notes Qualified Financing for an amount of shares equal to the number of shares received by the holder in the 2017 Convertible Notes Qualified Financing at the same price per share of the securities issued in the 2017 Convertible Notes Qualified Financing. Lastly, if a change of control transaction occurred prior to the earlier of a 2017 Convertible Notes Qualified Financing or the 2017 Convertible Notes Maturity Date, the 2017 Convertible Notes would have, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction, or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by the Board as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms-length transaction or (ii) at the per share consideration to be paid in such transaction. Change of control meant a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets. The New Warrants would have also become exercisable upon a change of control transaction for an amount of shares equal to the number of shares received by the holder upon conversion in connection with such transaction at the same price per share that the 2017 Convertible Notes converted in the change of control transaction. The December 2017 amendment resulted in a substantial modification to the original 2017 Convertible Notes whereby the maturity date was moved up to December 2018 from October 2022 and the terms associated with the embedded features were revised as described above. The Company recorded the 2017 Convertible Note amendment under the provisions of extinguishment accounting. As of January 1, 2018, there remained a debt discount of $26,085 of which $6,575 and $19,510 was amortized during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The 2017 Convertible Notes contained a conversion discount in the event of a 2017 Convertible Notes Qualified Financing to equal the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing. The embedded feature qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the 2017 Convertible Notes in the amount of $168,384 for the convertible debt issued during the nine month transition period ended September 30, 2018; there were no issuances of 2017 Convertible Notes during the year ended September 30, 2019. The discount was being amortized to interest expense over the amended term of the 2017 Convertible Notes through December 31, 2018 using the straight-line method which approximated the effective interest method. The amortization expense was $62,158 and $143,166 during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $111,195 and $11,020 during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The New Warrants were deemed to be free-standing instruments and were accounted initially as a liability given the variable number of shares issuable in connection with a change of control conversion event and ultimately as equity upon conversion of the 2017 Convertible Notes on February 28, 2019 discussed above. A Monte Carlo simulation model was used to estimate the aggregate fair value of the New Warrants up to the conversion date of the 2017 Convertible Notes. Input assumptions used were as follows: risk-free interest rate of 2.52% and 2.94% as of February 28, 2019 and September 30, 2018, respectively; expected volatility of 50% as of February 28, 2019 and September 30, 2018; expected life of 5.0 and 5.21 years as of February 28, 2019 and September 30, 2018, respectively; and expected dividend yield of 0% as of February 28, 2019 and September 30, 2018. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering the traded price, forward multiples from guideline public companies and recent private placement transactions, using allocation and marketability-discount methodologies. The 2017 Convertible Note proceeds assigned to the New Warrants were $442,151 during the nine month transition period ended September 30, 2018 and were recorded as a warrant liability. There were no proceeds assigned to warrants in connection with issuances of 2017 Convertible Notes during the year ended September 30, 2019. The discount was amortized to interest expense over the amended term of the 2017 Convertible Notes through December 31, 2018 using the straight-line method which approximated the effective interest method. The amortization expense was $163,060 and $375,076 for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The Company also recorded the fair value changes of the warrant liability associated with all of the 2017 Convertible Notes in the consolidated statements of operations which amounted to an expense of $18,568 and $39,770 for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. In connection with the 2017 Convertible Notes, the Company incurred original issuance costs in the amount of $8,133 which consisted of legal costs and were recorded as issuance cost discounts to the 2017 Convertible Notes, of which $1,431 and $2,944 was amortized to interest expense during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 9 - Stock-Based Compensation During the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, stock-based expense related to the stock options, restricted stock units and stock awards was included in general and administrative and research and development costs as follows in the accompanying consolidated statements of operations: 2019 2018 General and administrative $ 357,318 $ 480,653 Research and development 134,431 5,467 Total stock-based compensation expense $ 491,749 $ 486,120 The Company's 2016 and 2017 Equity Incentive Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company initially reserved 2,292,265 shares of common stock for issuance under the 2016 and 2017 Equity Incentive Plans on a combined basis. Evergreen provision Under the 2017 Plan, the shares reserved automatically increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. "Fully Diluted Shares" as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2019, 498,848 shares were added to the 2017 Plan as a result of the evergreen provision. Stock Options During the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, 675,667 and 2,500 stock options were granted to employees, directors and consultants at a weighted average exercise price of $2.32 and $5.34 per share, respectively. The stock options granted during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018 had a weighted average grant date fair value of $1.13 and $2.48 per share, respectively, with the vesting period ranging from being immediate to four years. The options expire ten years from the date of grant. The following table summarizes the Company's stock option plan activity for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018 as follows: Weighted- Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (years) Value(1) Outstanding at December 31, 2017 365,716 $ 0.03 9.3 $ 908,920 Granted 2,500 $ 5.34 — Exercised — $ — — Forfeited/Cancelled — $ — — Outstanding at September 30, 2018 368,216 $ 0.07 8.6 $ 820,862 Granted 675,667 $ 2.32 — Exercised (198,043 ) $ 0.27 — Forfeited/Cancelled — — — Outstanding at September 30, 2019 845,840 $ 1.82 9.0 $ 343,406 Vested and exercisable at September 30, 2019 458,311 $ 1.42 8.7 $ 343,406 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2019 and 2018 of $1.87 and $2.30 per share, respectively. As of September 30, 2019, 658,730 and 271,201 outstanding and vested options, respectively, have no intrinsic value. The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: 2019 2018 Expected stock price volatility 50.4 % 49.8 % Expected life of options (years) 5.6 5.0 Expected dividend yield 0 % 0 % Risk free interest rate 2.4 % 2.8 % During the year ended September 30, 2019, 288,138 stock options vested having a weighted average grant date fair value per option of $1.11. During the nine month transition period ended September 30, 2018, 2,500 stock options vested with the weighted average grant date fair value per option of $2.48. During the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, no options were forfeited. Restricted Stock Units The Company issued 42,018 restricted stock units ("RSUs") in June 2019 to members of its board of directors that vest monthly over one year upon grant of which 10,503 RSUs had vested as of September 30, 2019 for which common stock was issued. The grant date fair value of the RSUs was $2.38 per unit. There were no RSUs issued during the nine month transition period ended September 30, 2018. The total expense for the year ended September 30, 2019 related to these RSU's was $32,223. Other Stock-Based Awards A total of 250,000 shares of common stock were reserved in February 2018 as a result of a consulting agreement for investor relations services executed in February 2018. Under the agreement, 50,000 and 200,000 shares of common stock were awarded during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively, subject to time-based vesting conditions. The compensation expense related to the vested common shares was included in the total stock-based compensation expense referenced above which totaled $115,000 and $469,500 during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The expense was based on the fair value of the underlying common stock at the point of vesting which, on a weighted average basis, was $2.30 and $2.35 per share during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. As of November 2018, all shares under the February 2018 share reserve were issued from the Company's authorized but unissued shares, but were not eligible to be issued under the 2016 or 2017 Equity Incentive Plan reserves. In addition, the Company previously had formal obligations to issue future common stock options relating to several consulting agreements. A total of 38,874 stock options were granted in May 2019 related to those consulting agreements. The corresponding stock-based compensation expense related to the stock-based awards was included in research and development expense in the accompanying consolidated statements of operations. As of September 30, 2019, 1,489,759 shares were available for future issuance on a combined basis under the 2016 and 2017 Equity Incentive Plans. Unrecognized stock-based compensation was $473,643 as of September 30, 2019. The unrecognized share-based expense is expected to be recognized over a weighted average period of 2.5 years.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	NOTE 10 - Stockholders' Deficit 2018 Private Placement From July 9, 2018 through November 30, 2018 (the final closing), the Company entered into subscription agreements (each, a "Purchase Agreement") with certain accredited investors (the "Purchasers"), pursuant to which the Company, in a private placement (the "2018 Private Placement"), agreed to issue and sell to the Purchasers units (each, a "Unit"), each consisting of (i) 1 share (each, a "Share") of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2018 Warrants"). The initial closing of the 2018 Private Placement was consummated on July 9, 2018. As of the termination of the 2018 Private Placement on December 12, 2018, the Company had issued and sold an aggregate of 615,200 Units at a price of $2.50 per Unit to the Purchasers, for total gross proceeds to the Company of $1,538,000 before deducting offering expenses (170,000 and 445,200 Units were sold during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively). Under the Purchase Agreement, the Company agreed to use the net proceeds from the 2018 Private Placement to pay the outstanding principal and accrued interest on its 2017 Convertible Notes if such notes did not convert prior to maturity, to pay the principal on its unsecured term loans, for research and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate purposes. The Company granted the Purchasers indemnification rights with respect to its representations, warranties and agreements under the Purchase Agreement. The 2018 Warrants are exercisable beginning on the date of issuance and will expire on July 9, 2023, five years from the date of the first closing. The 2018 Warrants were accounted for as free standing equity instruments and classified as additional paid-in capital in the accompanying consolidated balance sheets based on their relative fair value to the underlying common shares issued. The relative fair value of the 2018 Warrants issued during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018 was $115,674 and $288,106, respectively, and was based on the Black-Scholes pricing model. Input assumptions used were as follows on a weighted average basis: a risk-free interest rate of 2.9% and 2.8% during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively; expected volatility of 49.8% during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018; expected life of 4.6 years and 4.9 years during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively; and expected dividend yield of 0% during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering both the traded price and forward multiples from guideline public companies, using allocation and marketability-discount methodologies. In February 2019, the Company amended its engagement letter with one of its placement agents in the 2018 Private Placement, HRA Capital ("HRA"), acting through its affiliate, Corinthian Partners, LLC, each of which are affiliates of one of the Company's greater than 5% stockholders. Pursuant to the original agreement (prior to the amendment), the Company agreed to pay HRA 10% of the gross proceeds (the "HRA Fee") received by the Company in subsequent private placement transactions from investors with whom HRA or Corinthian Partners, LLC had material contact with for purposes of the engagement letter (the "Prospects"), provided such compensation would only be paid in connection with private placement transactions that closed within 12 months of the expiration of the engagement letter (the "Tail Period"). The Company agreed to issue to HRA warrants to purchase shares of Common Stock (or common stock equivalents) in an amount equal to 10% of the shares purchased by Prospects during the Tail Period ("HRA Warrants"). In February 2019, the Company and HRA agreed (i) to extend the Tail Period until June 30, 2019, (ii) to modify the HRA Fee so that HRA is entitled to receive a cash fee equal to 8% of the gross proceeds received by the Company from Prospects in all subsequent private placement transactions and (iii) to modify the HRA Warrants so that they are exercisable to purchase shares of Common Stock (or common stock equivalents) in an amount equal to 8% of the shares of Common Stock purchased by Prospects in subsequent private placements (collectively, the "HRA Amendments"). Upon issuance, the HRA Warrants will be immediately exercisable and expire five years from the closing of the related transaction. In connection with the 2018 Private Placement, the Company recorded issuance costs in the amount of $18,320 and $173,067 during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. The issuance costs included commissions to the brokers equal to 8% of the gross proceeds from the sale of the Units that qualify for the commission which amounted to $6,440 and $83,800 during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. In addition to the brokers' commission, the issuance costs included the estimated value of the 5-year warrants to be issued to the brokers to purchase an amount of common stock equal to 8% of the total amount of qualifying Shares sold in the 2018 Private Placement at an exercise price of $3.00 per share upon the close of the 2018 Private Placement which resulted in 36,096 broker warrants being issued with a fair value of $31,418 on July 1, 2019. Lastly, third party legal costs in the amount $7,340 and $62,389 comprised the balance of the issuance costs incurred during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018, respectively. In connection with the 2018 Private Placement, the Company entered into registration rights agreements with each of the Purchasers pursuant to which the Company agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the 2018 Private Placement and the shares of common stock issuable upon exercise of the 2018 Warrants. The Company agreed to file such registration statement within 75 days of the final closing of the 2018 Private Placement. Each registration rights agreement included customary indemnification rights in connection with the registration statement. The registration statement was filed with the SEC on February 11, 2019, and declared effective by the SEC on February 28, 2019. 2019 Private Placement On December 12, 2018, the Board of Directors of the Company terminated the 2018 Private Placement. From December 28, 2018 through July 1, 2019, the Company entered into Subscription Agreements (each, a "2019 Purchase Agreement") with certain accredited investors (the "New Purchasers"), pursuant to which the Company, in a new private placement (the "2019 Private Placement"), agreed to issue and sell Units (the "2019 Units"), each consisting of (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2019 Warrants"), to the New Purchasers. The initial closing of the 2019 Private Placement was consummated on December 28, 2018. The Company issued and sold an aggregate of 2,338,179 Units at $2.50 per Unit to the New Purchasers, for total gross proceeds to the Company of approximately $5,845,448 before deducting offering expenses. The 2019 Private Placement was terminated on July 1, 2019. In connection with the 2019 Private Placement, the Company agreed to issue and sell to accredited investors up to a maximum of 4,000,000 2019 Units (the "Maximum Offering") at a price of $2.50 per 2019 Unit for total gross proceeds to the Company of up to $10,000,000. The Maximum Offering could have been increased by the Company in its sole discretion, without notice. If the Company had issued the Maximum Offering amount, 4,000,000 shares of common stock would have been issuable upon exercise of the 2019 Warrants. Under the 2019 Purchase Agreement, the Company had agreed to use the net proceeds from the 2019 Private Placement to pay the outstanding principal and accrued interest on its convertible promissory notes if such notes do not convert prior to maturity, to pay the principal on its unsecured term loans, for research and development, clinical studies, legal fees and sales and marketing expenses, as well as working capital and general corporate purposes. The Company has granted the New Purchasers indemnification rights with respect to its representations, warranties and agreements under the 2019 Purchase Agreement. The 2019 Warrants are exercisable beginning on the date of issuance and will expire on December 28, 2023, five years from the date of the first closing of the 2019 Private Placement. Prior to expiration, subject to the terms and conditions set forth in the 2019 Warrants, the holders may exercise the 2019 Warrants for shares of common stock by providing notice to the Company and paying the $3.00 per share exercise price for each share so exercised. The relative fair value of the 2019 Warrants issued was $1,593,559 during the year ended September 30, 2019, and was based on the Black-Scholes pricing model. Input assumptions used were on a weighted average basis as follows: a risk-free interest rate of 2.4%; expected volatility of 50.6%; expected life of 4.8 years; and expected dividend yield of 0%. The underlying stock price used in the analysis was on a non-marketable basis and was according to the market approach, considering traded price, forward multiples from guideline public companies and recent private placement transactions, using allocation and marketability-discount methodologies. In connection with the 2019 Private Placement, Paulson Investment Company, LLC ("Paulson") received a cash commission equal to 12% of the gross proceeds from the sale of the 2019 Units sold by Paulson. In addition to the brokers' commission, the Company issued 193,417 warrant shares to Paulson to purchase an amount of common stock equal to 10% of the total amount of common stock sold in the 2019 Private Placement at an exercise price of $2.75 per share with a term of 5 years upon the termination of the 2019 Private Placement. HRA received a cash commission equal to 8% of the gross proceeds from the sale of the 2019 Units sold by HRA. In addition to the brokers' commission, the Company issued 17,760 warrant shares to HRA to purchase an amount of common stock equal to 8% of the total amount of common stock sold by HRA in the 2019 Private Placement at an exercise price of $3.00 per share with a term of 5 years upon the termination of the 2019 Private Placement. Lastly, in July 2019, the Company agreed to compensate HRA with additional 5-year warrants to purchase an amount of common stock equal to 135,512 shares at an exercise price of $2.00 per share for HRA's ultimate participation in the 2019 Private Placement. The issuance costs incurred during the year ended September 30, 2019 under the 2019 Private Placement were $1,150,359. Issuance costs incurred through September 30, 2019 included cash commissions equal to $649,654 and third party legal costs in the amount of $153,286. In addition, issuance costs included the value of the 5-year warrants in the amount of $347,419 that were issued on July 1, 2019 to the brokers to purchase an amount of common stock equal to 346,689 shares. Warrant Activity and Summary The following table summarizes warrant activity during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: Exercise Price Weighted Average Weighted Average Warrants Per Warrant Exercise Price Term (years) Outstanding and exercisable at December 31, 2017 189,750 $ 1.80 $ 1.80 5.5 Issued 2,737,822 $ 1.80 - 3.00 $ 2.00 Exercised — $ — $ — Forfeited — $ — $ — Outstanding and exercisable at September 30, 2018 2,927,572 $ 1.80 - 3.00 $ 1.98 3.39 Issued 4,569,322 $ 2.00 - 3.00 $ 2.87 — Exercised (231,296 ) $ 1.80 $ 1.80 — Forfeited — $ — $ — — Outstanding and exercisable at September 30, 2019 7,265,598 $ 1.80 - 3.00 $ 2.55 3.60 The following table summarizes information about warrants outstanding at September 30, 2019: Exercise Price Number Outstanding Weighted Average Remaining Contractual Number Exercisable at September 30, 2019 $ 1.80 2,251,076 2.15 2,251,076 $ 2.00 135,512 4.76 135,512 $ 2.50 839,179 4.42 839,179 $ 2.75 193,417 4.76 193,417 $ 3.00 3,846,414 4.18 3,846,414 Total 7,265,598 7,265,598

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 - Income Taxes The effective tax rate for the Company for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018 was zero percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations for the Company is as follows: 2019 2018 Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax, net of federal benefit (7.7 ) (7.7 ) Warrant expense 2.5 9.4 Disqualified interest and other (0.6 ) 1.0 Research credits (2.0 ) (1.5 ) Valuation allowance 28.8 19.8 Effective tax rate — % — % Significant components of the Company's deferred tax assets and liabilities are summarized in the tables below as of September 30, 2019 and 2018: 2019 2018 Deferred tax assets: Federal and state operating loss carryforwards $ 3,528,712 $ 1,837,375 Acquired intangibles 16,221 10,116 Accruals and other 40,113 73,763 Convertible notes — 28,863 Research and development credit carryforwards 275,343 140,553 Stock-based compensation 90,819 24,598 Total deferred tax assets 3,951,208 2,115,268 Valuation allowance (3,951,208 ) (2,115,268 ) Net deferred tax assets $ — $ — As of September 30, 2019 and 2018, the Company had gross deferred tax assets of approximately $3,951,000 and $2,115,000, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of approximately $3,951,000 and $2,115,000 as of September 30, 2019 and 2018, respectively. The U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. As of September 30, 2019 and 2018, the Company's federal net operating loss carryforwards were approximately $12,277,000 and $6,393,000, respectively. The Company had federal research credit carryforwards as of September 30, 2019 and 2018 of approximately $166,000 and $83,000, respectively. The federal net operating loss incurred prior to January 1, 2018 and tax credit carryforwards will begin to expire in 2036 if not utilized. Federal net operating losses incurred after December 31, 2017 will not expire. As of September 30, 2019 and 2018, the Company had state net operating loss carryforwards of approximately $12,277,000 and $6,393,000, respectively. The Company had state research credit carryforwards of approximately $110,000 and $57,000 as of September 30, 2019 and 2018, respectively. The state net operating loss carryforwards will begin to expire in 2031, if not utilized, and the state research credit carryforwards will begin to expire in 2032 if not utilized. Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more "5-percent shareholders" increase their ownership, in the aggregate, by more than 50 percentage points over a 36-month testing period or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization. In accordance with ASC 740, Income Taxes In accordance with this guidance, the Company has adopted a policy under which, if required to be recognized in the future, interest related to the underpayment of income taxes will be classified as a component of interest expense and any related penalties will be classified in operating expenses in the consolidated statements of operations. The Company's corporate returns are subject to examination for the 2016, 2017 and 2018 tax years for federal and subject to examination for the 2016, 2017 and 2018 tax years in one state jurisdiction.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Sep. 30, 2019
Retirement Benefits [Abstract]
Defined Contribution Plan	NOTE 12 - Defined Contribution Plan The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through September 30, 2019. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are 100% vested upon contribution. Discretionary employer matches to employee deferrals vest over a six year period beginning on the second anniversary of an employee’s date of hire. Discretionary profit sharing contributions vest over a five year period beginning on the first anniversary of an employee’s date of hire. The amount of matching contributions made during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018 was a benefit reduction of $(4,359) and $7,779, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 - Subsequent Events Facility Lease On October 7, 2019, the Company entered into a lease agreement (the "Lease") with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the "Landlord") pursuant to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the "Premises"). The Company took possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after such date, unless terminated earlier (the "Term"). The initial base rent for the Premises is $6,410 per month for the first 17 months, increasing to $7,076 per month by the end of the Term, and adjustable in accordance with the terms of the lease. In addition, as long as the Company is not in default under the Lease Agreement, the Company shall be entitled to an abatement of its base rent for the first 5 months. In addition, the Company will pay its pro rata share of the Landlord's annual operating expenses associated with the premises, calculated as set forth in the Lease. Common Stock Offering On October 23, 2019, the Company entered into Securities Purchase Agreements with certain accredited investors, pursuant to which the Company, in a private placement, has issued and sold 141,666 shares of the Company's common stock to the accredited investors at a price of $1.80 per share, for gross proceeds amounting to $0.3 million before deducting offering expenses. In connection with the private placement, the Company has agreed to issue and sell to accredited investors up to a maximum of 555,555 shares for total gross proceeds to the Company of up to $1,000,000. The Company intends to use the net proceeds from this private placement for funding operations or working capital and general corporate purposes. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the private placement within 60 days of the termination of the private placement. Paulson Convertible Notes Offering On November 1, 2019, the Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement, agreed to issue and sell to the investors 13% convertible promissory notes (each, a "Paulson Note" and collectively, the "Paulson Notes") and warrants (each, a "Paulson Warrant" and collectively, the "Paulson Warrants") to purchase shares of the Company's common stock. The initial closing of the private placement was consummated on November 1, 2019, and, on that date and through December 3, 2019, the Company issued Paulson Notes in an aggregate principal amount of $3,234,800 to the Subscribers for gross proceeds equaling the principal amount. The private placement terminated on December 3, 2019. The Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on May 1, 2020. If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the "Qualified Financing"), each subscriber shall have the option to convert the outstanding principal and accrued and unpaid interest of such subscriber's Paulson Note (the "Outstanding Balance") into the securities issued by the Company in such Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the Qualified Financing and (B) the ten day volume weighted average closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the maturity date, the Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets. Each Paulson Warrant grants the holder the option to purchase the number of shares of common stock equal to (i) 0.5 multiplied by (ii) the principal amount of such subscriber's Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. As of the final closing on December 3, 2019, the Company issued Paulson Warrants exercisable for 864,913 shares of Common Stock in connection with all closings of the private placement. The Paulson Warrants are immediately exercisable and expire on November 1, 2022. The exercise price is subject to adjustment in the event of any stock dividends or splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein. In connection with the private placement, Paulson Investment Company ("Paulson") will receive a cash commission equal to 12% of the gross proceeds from the sale of the Paulson Notes, and 10-year warrants to purchase an amount of Common Stock equal to 15% of the total amount of shares of Common Stock into which the Paulson Notes are convertible, at an exercise price equal to the offering price of the Company's securities in the next Qualified Financing.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America. In September 2018, the Board of Directors of the Company, pursuant to the bylaws and based upon the recommendation of its Audit Committee, approved a change in the Company's fiscal year end from December 31 to September 30. The Company's fiscal year now begins on October 1 and ends on September 30 of each year, starting on October 1, 2018 ("the nine month transition period"). For comparative purposes, the transition period of January 1, 2018 to September 30, 2018 is included in the consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC").
Management's Use of Estimates	Management's Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company's cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. The Company has not experienced any losses on its deposits since inception, and management believes that minimal credit risk exists with respect to these financial institutions. As of September 30, 2019, the Company had $11,749 of deposits in excess of federally insured amounts.
Common Stock Valuation	Common Stock Valuation As of September 30, 2019, the Company is utilizing pricing as quoted on the OTC Market as the basis for the fair value of the Company's common stock. Prior to September 30, 2019, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants' Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock (the "AICPA Valuation Framework"). The valuation methodology included estimates and assumptions that required the Company's judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, and the likelihood of achieving a liquidity event, such as an offering or sale. Significant changes to the key assumptions used in the valuations would result in different fair values of common stock at each of those valuation dates. Prior to September 30, 2019, the Company estimated its enterprise value on a continuing operations basis, using the market approach, with certain adjustments relating to the thinly traded status of the Company. The traded price of the Company was deemed not to be an entirely reliable indication of fair market value given the lack of trading liquidity. Therefore, in addition to applying partial weighting to the traded price, the Company relied on forward revenue multiples from guideline public companies ("GPC") for calendar years 2019 through 2021 and on the sales price of the Company's common stock in recent private placement transactions (see Note 10 – Stockholders' Deficit). The resulting equity value from the GPC method portion was allocated to common stock using the option pricing method, and a discount for lack of marketability was applied. Based on the above methodology and weightings, the Company derived a valuation conclusion that ranged from $2.05 to $2.52 per common share for the periods presented through June 30, 2019, the last date for which an evaluation was performed under the AICPA Valuation Framework. The fair value the Company's common stock is used as an input into the fair value determination of the warrants, stock option or other equity awards that the Company has issued or are outstanding liabilities at a reporting date.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company's accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. As of September 30, 2019 and 2018, the fair values of cash, prepaids and other assets, accounts payable, accrued expenses and the unsecured loans, while outstanding, approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the convertible promissory notes of the Company, while outstanding, was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and the premium conversion derivatives associated with the convertible promissory notes of the Company, while outstanding, were based on both the estimated fair value of our common stock of $2.29 and $2.30 per share as of their conversion on February 28, 2019 and as of September 30, 2018, respectively, and cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and are based on Level 3 inputs. There were no transfers between fair value hierarchy levels during the year ended September 30, 2019 and the nine month transition period ended September 30, 2018. The fair value of financial instruments measured on a recurring basis is as follows: As of September 30, 2018 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 817,155 $ — $ — $ 817,155 Premium conversion derivatives 308,395 — — 308,395 Total liabilities at fair value $ 1,125,550 $ — $ — $ 1,125,550 The following table provides a roll-forward of the warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis using unobservable level 3 inputs for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: 2019 2018 Warrant liability Balance as of beginning of period $ 817,155 $ 1,381,465 Value assigned to warrants in connection with convertible promissory and short-term notes — 579,873 Change in fair value of warrant liability 18,568 35,235 Reclassification to equity (835,723 ) (1,179,418 ) Balance as of end of period $ — $ 817,155 2019 2018 Premium debt conversion derivatives Balance as of beginning of period $ 308,395 $ 462,174 Value assigned to the underlying derivatives in connection with convertible promissory notes — 218,052 Change in fair value of premium debt conversion derivatives 111,195 (371,831 ) Reclassification to equity upon conversion of convertible promissory notes (419,590 ) — Balance as of end of period $ — $ 308,395
Intellectual Property	Intellectual Property The Company has entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for equipment ranges from three to five years and three years for software. Tangible assets acquired for research and development activities and have alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. Software purchased for internal use consists primarily of amounts paid for perpetual licenses to third-party software providers and installation costs. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets, which consist of licensed intellectual property and property and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company determined that no impairment triggers existed during the periods ended September 30, 2019 and 2018.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are recorded as a reduction of the convertible promissory notes and short-term notes when applicable. Amortization of debt issuance costs is calculated using the straight-line method over the term of the convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying consolidated statements of operations.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, Research and Development. Lastly, de minimis income from the sale of prototype products and related materials are offset against research and development expenses.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation Equity
Warrant Liability	Warrant Liability The Company issued warrants to purchase equity securities in connection with the issuance of convertible promissory notes (See Note 7– Short-Term Promissory Notes and Unsecured Loans and Note 8 – Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value when the number of shares is not fixed and determinable in cases where warrant pricing protections in future equity financings are not available to other common stockholders. Additionally, issuance costs associated with the warrant liability are expensed as incurred and reflected as interest expense in the accompanying consolidated statements of operations. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants for any period when pricing protections in future equity financings remain in place, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders' (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability, when outstanding, is recognized in the consolidated statements of operations.
Premium Debt Conversion Derivatives	Premium Debt Conversion Derivatives The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method. The separated embedded derivatives are accounted for separately on a fair value basis. The Company records the fair value changes of separated embedded derivatives at each reporting period in the consolidated statements of operations (See Note 7– Short-Term Promissory Notes and Unsecured Loans and Note 8 – Convertible Promissory Notes and Warrant Agreements). The Company determined that the redemption features under the convertible promissory notes qualified as embedded derivatives and therefore separated from the debt host with regard to the convertible promissory notes.
Income Taxes	Income Taxes For the Company, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.
Net Loss Per Share	Net Loss Per Share For the Company, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company's convertible promissory notes, warrants and stock options and restricted stock units are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the warrants, restricted stock units and stock options. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the year ended September 30, 2019 or the nine month transition period ended September 30, 2018 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018. The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the year ended September 30, 2019 and the nine month transition period ended September 30, 2018: 2019 2018 Warrants 7,265,598 2,927,572 (1) Stock options 845,840 368,216 Restricted stock units 31,515 — (1) As of September 30, 2018, there were additional potential warrants to be included which would be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2017 and July 2018. The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods. The Company plans to adopt the standard on October 1, 2019, and will apply the modified retrospective approach to each lease in existence at the adoption date to the extent a lease is subject to this guidance. As such, the Company would not restate comparative periods and would recognize any cumulative adjustment to retained earnings on the date of the adoption. The Company also plans to elect the package of practical expedients provided under the standard. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , Revenue from Contracts with Customers . In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement . ● Removals: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. ● Modifications: for investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee's assets and the date when restrictions from redemption might lapse only if the investee has communicated the timing to the entity or announced the timing publicly; and the amendments clarify that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. ● Additions: the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period; and the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This guidance is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should all be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently evaluating the impact of the new guidance on its financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of fair value of financial instruments measured on a recurring basis	As of September 30, 2018 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 817,155 $ — $ — $ 817,155 Premium conversion derivatives 308,395 — — 308,395 Total liabilities at fair value $ 1,125,550 $ — $ — $ 1,125,550
Schedule of warrant liability and premium debt conversion derivatives measured at fair value on a recurring basis	2019 2018 Warrant liability Balance as of beginning of period $ 817,155 $ 1,381,465 Value assigned to warrants in connection with convertible promissory and short-term notes — 579,873 Change in fair value of warrant liability 18,568 35,235 Reclassification to equity (835,723 ) (1,179,418 ) Balance as of end of period $ — $ 817,155 2019 2018 Premium debt conversion derivatives Balance as of beginning of period $ 308,395 $ 462,174 Value assigned to the underlying derivatives in connection with convertible promissory notes — 218,052 Change in fair value of premium debt conversion derivatives 111,195 (371,831 ) Reclassification to equity upon conversion of convertible promissory notes (419,590 ) — Balance as of end of period $ — $ 308,395
Schedule of computation of diluted net loss per share	2019 2018 Warrants 7,265,598 2,927,572 (1) Stock options 845,840 368,216 Restricted stock units 31,515 — (1) As of September 30, 2018, there were additional potential warrants to be included which would be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.

Intangibles and Property and _2

Intangibles and Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Useful Life Net Intangibles, December 31, 2017 12-13 years $ 216,372 Less: amortization (16,291 ) Net Intangibles, September 30, 2018 200,081 Less: amortization (21,243 ) Net Intangibles, September 30, 2019 $ 178,838
Schedule of property and equipment	As of September 30, 2019 2018 Equipment $ 56,457 $ — Software 1,895 — Total property and equipment 58,352 — Less accumulated depreciation (6,326 ) — Property and equipment, net $ 52,026 $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of accrued expenses	As of September 30, 2019 2018 License fees $ — $ 65,000 Legal services 228,709 833,470 Accrued issuance costs 50,400 204,000 Accrued payroll 171,087 276,639 Other 167,525 211,913 $ 617,721 $ 1,591,022

Short-Term Promissory Notes a_2

Short-Term Promissory Notes and Unsecured Loans (Tables)	12 Months Ended
	Sep. 30, 2019
Short-term Promissory Notes And Unsecured Loans
Schedule of short-term promissory notes, unsecured loans	As of September 30, 2019 2018 Unsecured loans $ — $ 283,000

Convertible Promissory Notes _2

Convertible Promissory Notes and Warrant Agreements (Tables)	12 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of convertible promissory notes and warrant agreements	As of September 30, 2019 2018 2017 convertible promissory notes, net of discounts $ — $ 1,306,776 Accrued interest — 87,028 Total $ — $ 1,393,804

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of share-based compensation expense	2019 2018 General and administrative $ 357,318 $ 480,653 Research and development 134,431 5,467 Total stock-based compensation expense $ 491,749 $ 486,120
Schedule of stock option plan activity	Weighted- Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (years) Value(1) Outstanding at December 31, 2017 365,716 $ 0.03 9.3 $ 908,920 Granted 2,500 $ 5.34 — Exercised — $ — — Forfeited/Cancelled — $ — — Outstanding at September 30, 2018 368,216 $ 0.07 8.6 $ 820,862 Granted 675,667 $ 2.32 — Exercised (198,043 ) $ 0.27 — Forfeited/Cancelled — — — Outstanding at September 30, 2019 845,840 $ 1.82 9.0 $ 343,406 Vested and exercisable at September 30, 2019 458,311 $ 1.42 8.7 $ 343,406 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2019 and 2018 of $1.87 and $2.30 per share, respectively. As of September 30, 2019, 658,730 and 271,201 outstanding and vested options, respectively, have no intrinsic value.
Schedule of weighted-average assumptions used Black-Scholes option-pricing model	2019 2018 Expected stock price volatility 50.4 % 49.8 % Expected life of options (years) 5.6 5.0 Expected dividend yield 0 % 0 % Risk free interest rate 2.4 % 2.8 %

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of warrant activity	Exercise Price Weighted Average Weighted Average Warrants Per Warrant Exercise Price Term (years) Outstanding and exercisable at December 31, 2017 189,750 $ 1.80 $ 1.80 5.5 Issued 2,737,822 $ 1.80 - 3.00 $ 2.00 Exercised — $ — $ — Forfeited — $ — $ — Outstanding and exercisable at September 30, 2018 2,927,572 $ 1.80 - 3.00 $ 1.98 3.39 Issued 4,569,322 $ 2.00 - 3.00 $ 2.87 — Exercised (231,296 ) $ 1.80 $ 1.80 — Forfeited — $ — $ — — Outstanding and exercisable at September 30, 2019 7,265,598 $ 1.80 - 3.00 $ 2.55 3.60
Schedule of warrant outstanding	Exercise Price Number Outstanding Weighted Average Remaining Contractual Number Exercisable at September 30, 2019 $ 1.80 2,251,076 2.15 2,251,076 $ 2.00 135,512 4.76 135,512 $ 2.50 839,179 4.42 839,179 $ 2.75 193,417 4.76 193,417 $ 3.00 3,846,414 4.18 3,846,414 Total 7,265,598 7,265,598

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of reconciliation of income tax computed at the statutory federal income tax rate	2019 2018 Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax, net of federal benefit (7.7 ) (7.7 ) Warrant expense 2.5 9.4 Disqualified interest and other (0.6 ) 1.0 Research credits (2.0 ) (1.5 ) Valuation allowance 28.8 19.8 Effective tax rate — % — %
Schedule ofdeferred tax assets and liabilities	2019 2018 Deferred tax assets: Federal and state operating loss carryforwards $ 3,528,712 $ 1,837,375 Acquired intangibles 16,221 10,116 Accruals and other 40,113 73,763 Convertible notes — 28,863 Research and development credit carryforwards 275,343 140,553 Stock-based compensation 90,819 24,598 Total deferred tax assets 3,951,208 2,115,268 Valuation allowance (3,951,208 ) (2,115,268 ) Net deferred tax assets $ — $ —

Going Concern (Details)

Going Concern (Details) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Going Concern (Textual)
Accumulated deficit	$ 17,238,871	$ 10,457,710
Unsecured loan	528,000
Short-term promissory note	253,000
Convertible promissory note financing	1,625,120
Second convertible promissory note financing	1,540,000
Convertible promissory note, subscription	2,500,000
Convertible promissory note, subscription one	2,000,000
Gross proceeds	7,400,000
Maximum subscription amount	$ 11,800,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	Sep. 30, 2018USD ($)
Liabilities:
Warrant liability	$ 817,155
Premium conversion derivatives	308,395
Total liabilities at fair value	1,125,550
Level 1 [Member]
Liabilities:
Warrant liability
Premium conversion derivatives
Total liabilities at fair value
Level 2 [Member]
Liabilities:
Warrant liability
Premium conversion derivatives
Total liabilities at fair value
Level 3 [Member]
Liabilities:
Warrant liability	817,155
Premium conversion derivatives	308,395
Total liabilities at fair value	$ 1,125,550

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period	$ 817,155
Balance as of end of period - June 30		$ 817,155
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period	817,155	1,381,465
Value assigned to warrants in connection with convertible promissory and short-term notes		579,873
Change in fair value of warrant liability	18,568	35,235
Reclassification to equity	(835,723)
Balance as of end of period - June 30		$ 817,155

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - Debt Conversion Derivative [Member] - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of beginning of period	$ 308,395	$ 462,174
Value assigned to the underlying derivatives in connection with convertible promissory notes		218,052
Change in fair value of premium debt conversion derivatives	111,195	(371,831)
Reclassification to equity upon conversion of convertible promissory notes	(419,590)
Balance as of end of period		$ 308,395

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	7,265,598	2,927,572	[1]
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	845,840	368,216
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive computation of diluted net loss per share	31,515
[1]	As of September 30, 2018, there were additional potential warrants to be included which would be known, if and when a qualified financing event greater than $3 million or a change of control transaction occurs in the future.

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Sep. 30, 2019USD ($)Agreements	Feb. 28, 2019$ / shares	Sep. 30, 2018$ / shares
Summary of Significant Accounting Policies (Textual)
Deposits in excess of federally insured amounts | $	$ 11,749
Common stock valuation, description	The Company derived a valuation conclusion that ranged from $2.05 to $2.52 per common share for the periods presented through June 30, 2019, the last date for which an evaluation was performed under the AICPA Valuation Framework.
Number of licencing agreements | Agreements	2
Equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years
Equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	5 years
Software [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life	3 years
Estimate of fair value [Member]
Summary of Significant Accounting Policies (Textual)
Common stock, per shares | $ / shares		$ 2.29	$ 2.30

Commitments and Contingencies (

Commitments and Contingencies (Details)	12 Months Ended
	Sep. 30, 2019USD ($)
Commitments and Contingencies (Textual)
Facility lease term	11 months
Monthly lease rent	$ 4,763
Lease rent expense	$ 47,630
WARF license agreement, description	The Company is obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the WARF Agreement.

Intangibles and Property and _3

Intangibles and Property and Equipment (Details) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	$ 200,081	$ 216,372
Less: amortization	(21,243)	(16,291)
Ending Balance	$ 178,838	$ 200,081
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	13 years

Intangibles and Property and _4

Intangibles and Property and Equipment (Details 1) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Equipment	$ 56,457
Software	1,895
Total property and equipment	58,352
Less accumulated depreciation	(6,326)
Property and equipment, net	$ 52,026

Intangibles and Property and _5

Intangibles and Property and Equipment (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Intangibles (Textual)
Depreciation expense		$ 6,326
Anticipates amortization expense, description		The Company anticipates amortization expense of approximately $21,000 per year for fiscal year 2020 through 2024 based upon the two current license agreements.

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Payables and Accruals [Abstract]
License fees		$ 65,000
Legal services	228,709	833,470
Accrued issuance costs	50,400	204,000
Accrued payroll	171,087	276,639
Other	167,525	211,913
Total accrued expenses	$ 617,721	$ 1,591,022

Short-Term Promissory Notes a_3

Short-Term Promissory Notes and Unsecured Loans (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Debt Disclosure [Abstract]
Unsecured loans		$ 283,000

Short-Term Promissory Notes a_4

Short-Term Promissory Notes and Unsecured Loans (Details Textual) - USD ($)	Mar. 12, 2018	Dec. 31, 2018	Nov. 30, 2018	May 17, 2018	Mar. 20, 2018	Nov. 30, 2017	Aug. 31, 2017	Sep. 30, 2018	Sep. 30, 2019
Short-Term Promissory Notes and Unsecured Loan (Textual)
Aggregate gross proceeds of short-term unsecured promissory notes
Warrants expiration date	Nov. 21, 2021
Warrants exercisable, description	The holder the option to purchase up to the number of shares of capital stock of the Company equal to the product obtained by multiplying (i) the outstanding principal amount of the Amended and Restated Short-Term Note held by such holder and (ii) 0.75; at a per share exercise price of $1.80.
Warrant liability								$ 817,155
Replacement Warrants [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Fair value of warrants risk-free interest rate									2.65%
Fair value of warrants expected volatility									50.00%
Fair value of warrants expected life									3 years 4 months 20 days
Fair value of warrants expected dividend yield									0.00%
Fair value changes of warrant liability									$ 10,330
Loss on short-term notes extinguishment									$ 137,722
Unsecured Debt [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Short-term debt, description		The Company received gross proceeds from an unsecured loan represented by one promissory note in the amount of $100,000 from a stockholder owning over 5% of the Company's common stock. The loan was interest free and required that the Company repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or December 12, 2019. The loan was fully repaid by June 30, 2019.	The Company received cash gross proceeds from unsecured loans represented by two promissory notes in the amounts of $45,000 and $100,000 from a stockholder owning or affiliated with stockholders owning over 5% of the Company's common stock. The loans were interest free and required that the Company repay the principal in full on the earlier of the closing of an equity round of financing of the Company resulting in more than $5 million in gross proceeds or November 14, 2019. The loans were fully repaid by June 30, 2019.	The Company received cash proceeds of $168,000 from unsecured loans, represented by two promissory notes from a stockholder owning or affiliated with stockholders owning over 5% of the Company's common stock. The loans were interest free and required that the Company repay the principal in full on the earlier to occur of (i) May 17, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $5 million in gross proceeds. The loans included customary events of default provisions. The loans were fully repaid by June 30, 2019.	The Company received cash proceeds from an unsecured loan, represented by a promissory note, for $115,000 from a stockholder owning over 5% of the Company's common stock. The loan was interest free and the Company repaid the principal in full in the second quarter of 2019 as required on the earlier to occur of (i) March 20, 2019 or (ii) the closing of an equity round of financing of the Company that raises more than $3 million in gross proceeds. The loan included customary events of default provisions.
Cancellation Extinguishment And Conversion Of Short Term Notes [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Short-term notes conversion, description						The Short-Term Notes were amended to extend the maturity date from February 18, 2018 to July 31, 2018 and to increase warrant coverage to 189,750 common stock purchase warrants (as amended, the "Original Warrants"). The Original Warrants had a term of 5 years and an exercise price of $1.80 and would have been immediately exercisable upon maturity of the Short-Term Notes prior to the November 30, 2017 amendment.
Short-term Debt [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Aggregate gross proceeds of short-term unsecured promissory notes							$ 253,000
Short-term debt, description									(i) convert the outstanding principal and accrued and unpaid interest (the "Outstanding Balance") under the Short-Term Notes into shares of the Company's common stock based on the Outstanding Balance divided by $1.80 per share (the "Short-Term Note Conversion Shares"); (ii) cancel and extinguish the Short-Term Notes; and (iii) amend and restate the Replacement Warrants and Additional Warrants, as described more fully below, to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. Interest on principal during the nine month transition period ended September 30, 2018 up through the July 2, 2018 conversion date was $6,296. As consideration for the early conversion of the Short-Term Notes, the Company issued each subscriber a new warrant (the "Short-Term Note Payment Warrants"), exercisable for up to the number of shares of common stock equal to the number of Short-Term Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.
Converted into shares of common stock									144,053
Shares of common stock issuable upon exercise									477,856
Short-term payment warrants									$ 148,787
Fair value of warrants risk-free interest rate									2.65%
Fair value of warrants expected volatility									49.80%
Fair value of warrants expected life									3 years 4 months 20 days
Fair value of warrants expected dividend yield									0.00%
Additional warrants allocated	189,750
Warrants expiration date									Nov. 21, 2021
Loss on short-term notes extinguishment								148,787
Convertible notes bear interest at fixed rate	8.00%
Outstanding principal									$ 259,297
Warrant liability									148,052
Premium Conversion Derivative [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Value of premium conversion derivative	$ 49,668
Fair value changes of warrant liability								(49,668)
Short-term notes conversion, description	The Amended and Restated Short-Term Notes contained a 125% conversion premium in the event that a Short Term Note Qualified Financing occurred at a price under $2.25 per share.
Other Debt [Member]
Short-Term Promissory Notes and Unsecured Loan (Textual)
Loss on short-term notes extinguishment								$ 186,220
Adjustment to account for change in valuation									$ 1,170

Convertible Promissory Notes _3

Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Short-term Debt [Line Items]
Accrued interest		$ 87,028
Total		1,393,804
2017 convertible promissory notes, net of discounts [Member]
Short-term Debt [Line Items]
Total		$ 1,306,776

Convertible Promissory Notes _4

Convertible Promissory Notes and Warrant Agreements (Details Textual) - USD ($)	1 Months Ended			9 Months Ended	12 Months Ended
	Feb. 28, 2019	Jul. 02, 2018	Jan. 02, 2018	Sep. 30, 2018	Sep. 30, 2019	Jun. 30, 2017
Convertible Promissory Notes and Warrant Agreements (Textual)
Loss on convertible notes extinguishment				$ (1,314,487)	$ (553,447)
Conversion derivative related to convertible promissory notes				$ 168,384
New Warrants [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Fair value of warrants expected volatility				50.00%
Fair value of warrants expected life				5 years 2 months 16 days
Fair value of warrants expected dividend yield				0.00%
Convertible promissory note proceeds assigned to warrants				$ 442,151
Amortization expense				375,076	163,060
Fair value changes of warrant liability				39,770	$ 18,568
2017 Convertible Note Amendment [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Maturity date, description					Maturity date was moved up to December 2018 from October 2022
Discount amortization expense related to the bifurcated derivative				143,166	$ 62,158
Fair value changes on premium debt conversion derivative				11,020	111,195
Amortization relates to the discount attributed to the note modification in March 2018				$ 19,510	$ 6,575
Conversion rate discount associated with the applicable stock price in an offering					80.00%
Amount of remained a debt discount			$ 26,085
2017 Convertible Notes [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Convertible notes bear interest at fixed rate					8.00%
Principal amount					$ 1,540,000
Maturity date, description					Extend the maturity date from December 31, 2018 to June 30, 2019.
Description of outstanding principal and accrued interest					If the Company consummated an equity round of financing resulting in more than $3 million in gross proceeds before June 30, 2019 (the "2017 Convertible Notes Qualified Financing"), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes would have automatically converted into the securities issued by the Company in the 2017 Convertible Notes Qualified Financing equal to the outstanding principal and accrued interest on the 2017 Convertible Notes divided by 80% of the price per share of the securities issued by the Company in the 2017 Convertible Notes Qualified Financing.
Description of maximum voting power of surviving entity					Change of control meant a merger or consolidation with another entity in which the Company's stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.
Fair value of warrants risk-free interest rate	2.52%
Fair value of warrants expected volatility	50.00%
Fair value of warrants expected life	5 years
Fair value of warrants expected dividend yield	0.00%
Convertible notes conversion price per common share					$ 3
Loss on convertible notes extinguishment	$ 553,447
Outstanding principal and interest	$ 1,678,361
Convertible promissory notes converted into common stock	839,179
Shares of common stock issuable upon exercise of warrants	839,179
Issued new warrants exercisable common stock	839,179
Warrant exercise term	4 years 9 months 18 days
2017 Convertible Notes [Member] | New Warrants [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Fair value of warrants risk-free interest rate				2.94%
Fair value of warrants expected volatility				50.00%
Fair value of warrants expected life				5 years 2 months 16 days
Fair value of warrants expected dividend yield				0.00%
Orginal issuance cost and discount					$ 8,133
Interest on principal amount				$ 80,022	51,333
Amortization of debt issuance costs				2,944	$ 1,431
2016 Convertible Promissory Notes [Member]
Convertible Promissory Notes and Warrant Agreements (Textual)
Principal amount						$ 1,625,120
Warrants exercise price						$ 1.80
Warrants exercisable date of issuance and expire		Nov. 21, 2021
Fair value of warrants risk-free interest rate					2.65%
Fair value of warrants expected volatility					49.80%
Fair value of warrants expected life					3 years 4 months 20 days
Fair value of warrants expected dividend yield					0.00%
Bifurcation discount related to the premium conversion liability				70,324
Conversion agreements, description		(i) convert the Outstanding Balance under the Convertible Notes into shares of the Company’s common stock based on the Outstanding Balance divided by $1.80 per share (the “2016 Note Conversion Shares”); (ii) cancel and extinguish the Convertible Notes; and (iii) amend and restate the Warrants as defined below to make them immediately exercisable upon the conversion, at a per share exercise price equal to $1.80 per share. As consideration for the early conversion of the Convertible Notes, the Company issued each subscriber an additional new warrant (the “2016 Note Payment Warrants”), exercisable for up to the number of shares of common stock equal to the number of 2016 Note Conversion Shares received by such subscriber; at a per share exercise price of $1.80 per share.
Outstanding principal and interest					$ 1,804,064
Convertible promissory notes converted into common stock					1,002,258
Shares of common stock issuable upon exercise of warrants					2,004,516
Note payment warrants issued					$ 979,480
Warrant liability value of reclassified to equity					1,031,366
Interest on principal amount				65,727
Fair value changes related to underlying premium conversion derivative amounted to benefit				(333,183)
Fair value changes related to warrant liability amounted to benefit				$ (14,865)
Unamortized discount remaining on the convertible notes		$ 11,143			$ 979,480

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 486,120		$ 491,749
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense		$ 480,653	357,318
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense		$ 5,467	$ 134,431

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details 1) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2018	Sep. 30, 2019
Number of Options
Outstanding at December 31, 2017		365,716	368,216
Granted		2,500	675,667
Exercised			(198,043)
Forfeited/Cancelled
Outstanding at September 30, 2018		368,216	845,840
Vested and exercisable at September 30, 2019			458,311
Weighted Average Exercise Price
Outstanding at December 31, 2017		$ 0.03	$ 0.07
Granted		5.34	2.32
Exercised			0.27
Forfeited/Cancelled
Outstanding at September 30, 2018		$ 0.07	1.82
Vested and exercisable at September 30, 2019			$ 1.42
Weighted Average Remaining Contractual Term (years)
Outstanding at December 31, 2017		9 years 3 months 19 days
Outstanding at September 30, 2018		8 years 7 months 6 days	9 years
Vested and exercisable at September 30, 2019			8 years 8 months 12 days
Aggregate Intrinsic Value
Outstanding at December 31, 2017	[1]	$ 908,920	$ 820,862
Outstanding at September 30, 2018	[1]	$ 820,862	343,406
Vested and exercisable at September 30, 2019	[1]		$ 343,406
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of our common stock as of September 30, 2019 and 2018 of $1.87 and $2.30 per share, respectively. As of September 30, 2019, 658,730 and 271,201 outstanding and vested options, respectively, have no intrinsic value.

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details 2) - Equity Option [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Offsetting Assets [Line Items]
Expected stock price volatility	49.80%	50.40%
Expected life of options (years)	5 years	5 years 7 months 6 days
Expected dividend yield	0.00%	0.00%
Risk free interest rate	2.80%	2.40%

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details Textual) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	May 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Feb. 28, 2018
Stock-Based Compensation (Textual)
Stock options weighted average exercise price for shares of common stock granted		$ 5.34	$ 2.32
Fair value of common stock price per share		$ 2.48	$ 1.13
Stock-based services expense		$ 469,500	$ 115,000
Number of options, granted		2,500	675,667
Unrecognized stock-based compensation			$ 473,643
Unrecognized share-based expense is expected to be recognized over a weighted average period			2 years 6 months
Board of Directors [Member]
Stock-Based Compensation (Textual)
Restricted common stock not yet issued			42,018
Fair value of common stock price per share			$ 2.38
Vesting period			1 year
Vested shares			10,503
Compensation expense associated with restricted common stock			$ 32,223
Stock Option [Member]
Stock-Based Compensation (Textual)
Shares of common stock			658,730
Vested shares			271,201
Vested per share		$ 2.30	$ 1.87
Number of options, granted	38,874
Stock Option [Member] | 2017 Plan [Member]
Stock-Based Compensation (Textual)
Shares reserved, description			The shares reserved automatically increase on January 1st of each year, for a period of not more than ten years from the date the 2017 Plan is approved by the stockholders of the Company, commencing on January 1, 2019 and ending on (and including) January 1, 2027, to an amount equal to 13% of the fully-diluted shares outstanding as of December 31st of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1st of a given year to provide that there will be no January 1st increase in the share reserve for such year or that the increase in the share reserve for such year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. “Fully Diluted Shares” as of a date means an amount equal to the number of shares of common stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding awards under the 2017 Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of common stock, in each case as of the close of business of the Company on December 31 of the preceding calendar year. On January 1, 2019, 498,848 shares were added to the 2017 Plan as a result of the evergreen provision.
Stock Option [Member] | 2016 and 2017 Equity Incentive Plans [Member]
Stock-Based Compensation (Textual)
Reserved shares of common stock for issuance			2,292,265
Shares available for future grant issuance			1,489,759
Stock-Based Awards [Member]
Stock-Based Compensation (Textual)
Reserved shares of common stock for issuance				250,000
Vested shares		200,000	50,000
Common stock related to the award liability includes stock options		$ 2.35	$ 2.30
Risk Free Interest Rate [Member]
Stock-Based Compensation (Textual)
Fair value of common stock price per share		$ 2.48	$ 1.11
Shares of common stock		2,500	288,138

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Class of Warrant or Right [Line Items]
Outstanding, Weighted Average Term (years), Beginning	9 years 3 months 19 days
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding, Beginning	189,750	2,927,572
Issued	2,737,822	4,569,322
Exercised		(231,296)
Forfeited
Outstanding, Exercisable Ending	2,927,572	7,265,598
Exercise Price Per Warrant, Beginning	$ 1.80
Exercise Price Per Warrant, Issued Maximum	3	$ 3
Exercise Price Per Warrant, Issued Minimum	1.80	2
Exercise Price Per Warrant, Exercised		1.80
Exercise Price Per Warrant, Forfeited
Weighted Average Exercise Price, Beginning	1.80	1.98
Weighted Average Exercise Price, Issued	2	2.87
Weighted Average Exercise Price, Exercised		1.80
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Exercisable Ending	$ 1.98	$ 2.55
Outstanding, Weighted Average Term (years), Beginning	5 years 6 months	3 years 4 months 20 days
Outstanding, Weighted Average Term (years), Ending	3 years 4 months 20 days	3 years 7 months 6 days
Warrant [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning		$ 1.80
Exercise Price Per Warrant, Exercisable Ending	$ 1.80	1.80
Warrant [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price Per Warrant, Beginning		3
Exercise Price Per Warrant, Exercisable Ending	$ 3	$ 3

Stockholders' Deficit (Details

Stockholders' Deficit (Details 1)	12 Months Ended
	Sep. 30, 2019$ / sharesshares
Outstanding, Number of Warrant Shares	7,265,598
Outstanding, Number Exercisable	7,265,598
Warrant [Member] | One Exercise Price [Member]
Exercise Price | $ / shares	$ 1.80
Outstanding, Number of Warrant Shares	2,251,076
Outstanding, Weighted Average Remaining Contractual life (Years)	2 years 1 month 24 days
Outstanding, Number Exercisable	2,251,076
Warrant [Member] | Two Exercise Price [Member]
Exercise Price | $ / shares	$ 2
Outstanding, Number of Warrant Shares	135,512
Outstanding, Weighted Average Remaining Contractual life (Years)	4 years 9 months 3 days
Outstanding, Number Exercisable	135,512
Warrant [Member] | Three Exercise Price [Member]
Exercise Price | $ / shares	$ 2.50
Outstanding, Number of Warrant Shares	839,179
Outstanding, Weighted Average Remaining Contractual life (Years)	4 years 5 months 1 day
Outstanding, Number Exercisable	839,179
Warrant [Member] | Four Exercise Price [Member]
Exercise Price | $ / shares	$ 2.75
Outstanding, Number of Warrant Shares	193,417
Outstanding, Weighted Average Remaining Contractual life (Years)	4 years 9 months 3 days
Outstanding, Number Exercisable	193,417
Warrant [Member] | Five Exercise Price [Member]
Exercise Price | $ / shares	$ 3
Outstanding, Number of Warrant Shares	3,846,414
Outstanding, Weighted Average Remaining Contractual life (Years)	4 years 2 months 5 days
Outstanding, Number Exercisable	3,846,414

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details Textual) - USD ($)	Jul. 01, 2019	Dec. 12, 2018	Nov. 30, 2018	Jul. 01, 2019	Feb. 28, 2019	Sep. 30, 2018	Sep. 30, 2019
2019 Private Placement [Member]
Class of Stock [Line Items]
Fair value of warrant issued							$ 1,593,559
Maximum offering of units under private placement							4,000,000
Maximum offering, units per share							$ 2.50
Risk free interest rate							2.40%
Expected stock price volatility							50.60%
Expected life of years							4 years 9 months 18 days
Expected dividend yield							0.00%
Cost of issuance							$ 1,150,359
Issuance cost commission, percentage							8.00%
Issuance cost commission amounting							$ 649,654
Exercise price, per share							$ 3
Common stock purchase price, per share							10.00%
Estimated value of warrants excercise price issued, term							5 years
Private placement exercise price							$ 2.75
Broker warrants to be issued shares	346,689
Legal costs related to private placement issuance costs							$ 153,286
Warrants issued, value							$ 347,419
2019 Private Placement [Member] | Paulson [Member]
Class of Stock [Line Items]
Issuance cost commission, percentage							12.00%
Estimated value of warrants excercise price issued, term							5 years
Private placement transaction, description							HRA received a cash commission equal to 8% of the gross proceeds from the sale of the 2019 Units sold by HRA. In addition to the brokers' commission, the Company issued 17,760 warrant shares to HRA to purchase an amount of common stock equal to 8% of the total amount of common stock sold by HRA in the 2019 Private Placement at an exercise price of $3.00 per share with a term of 5 years upon the termination of the 2019 Private Placement. Lastly, in July 2019, the Company agreed to compensate HRA with additional 5-year warrants to purchase an amount of common stock equal to 135,512 shares at an exercise price of $2.00 per share for HRA's ultimate participation in the 2019 Private Placement.
Warrants shares issued							193,417
2019 Private Placement [Member] | Warrant [Member]
Class of Stock [Line Items]
Maximum shares of common stock issuable under private placement							4,000,000
Maximum potential gross proceeds from financing							$ 10,000,000
Private Placement [Member]
Class of Stock [Line Items]
Offering price, per share		$ 2.50
Gross proceeds from private placement		$ 5,845,448
Private placement transaction, description		(i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2019 Warrants"), to the New Purchasers.
Shares issued under private placement		2,338,179
2018 Private Placement [Member]
Class of Stock [Line Items]
Purchase agreement, description			(i) 1 share (each, a "Share") of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2018 Warrants").
Offering price, per share		$ 2.50
Fair value of warrant issued						$ 288,106	$ 115,674
Risk free interest rate						2.80%	2.90%
Expected stock price volatility						49.80%	49.80%
Expected life of years						4 years 10 months 25 days	4 years 7 months 6 days
Expected dividend yield						0.00%	0.00%
Cost of issuance						$ 173,067	$ 18,320
Issuance cost commission, percentage							8.00%
Exercise price, per share							$ 3
Estimated value of warrants excercise price issued, term							5 years
Units sold under private placement						445,200	170,000
Gross proceeds from private placement		$ 1,538,000
Broker warrants to be issued shares				36,096
Private placement transaction, description					(i) to extend the Tail Period until June 30, 2019, (ii) to modify the HRA Fee so that HRA is entitled to receive a cash fee equal to 8% of the gross proceeds received by the Company from Prospects in all subsequent private placement transactions and (iii) to modify the HRA Warrants so that they are exercisable to purchase shares of Common Stock (or common stock equivalents) in an amount equal to 8% of the shares of Common Stock purchased by Prospects in subsequent private placements (collectively, the "HRA Amendments"). Upon issuance, the HRA Warrants will be immediately exercisable and expire five years from the closing of the related transaction.
Shares issued under private placement		615,200
Legal costs related to private placement issuance costs						$ 62,389	$ 7,340
Brokerage commission						$ 83,800	$ 6,440
Percentage of cash commission and broker warrants							8.00%
Payment for HRA fee, description					The Company amended its engagement letter with one of its placement agents in the 2018 Private Placement, HRA Capital ("HRA"), acting through its affiliate, Corinthian Partners, LLC, each of which are affiliates of one of the Company's greater than 5% stockholders. Pursuant to the original agreement (prior to the amendment), the Company agreed to pay HRA 10% of the gross proceeds (the "HRA Fee") received by the Company in subsequent private placement transactions from investors with whom HRA or Corinthian Partners, LLC had material contact with for purposes of the engagement letter (the "Prospects"), provided such compensation would only be paid in connection with private placement transactions that closed within 12 months of the expiration of the engagement letter (the "Tail Period"). The Company agreed to issue to HRA warrants to purchase shares of Common Stock (or common stock equivalents) in an amount equal to 10% of the shares purchased by Prospects during the Tail Period ("HRA Warrants").
Brokerage warrants fair value				$ 31,418

Income Taxes (Details)

Income Taxes (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income tax, net of federal benefit	7.70%	7.70%
Warrant expense	9.40%	2.50%
Disqualified interest and other	1.00%	0.60%
Research credits	1.50%	2.00%
Valuation allowance	19.80%	28.80%
Effective tax rate

Income Taxes (Details1)

Income Taxes (Details1) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Deferred tax assets
Federal and state operating loss carryforwards	$ 3,528,712	$ 1,837,375
Acquired intangibles	16,221	10,116
Accruals and other	40,113	73,763
Convertible notes		28,863
Research and development credit carryforwards	257,343	140,553
Stock-based compensation	90,819	24,598
Total deferred tax assets	3,951,208	2,115,268
Valuation allowance	3,951,208	2,115,268
Net deferred tax assets

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Effective tax rate
Gross deferred tax assets	$ 2,115,268	$ 3,951,208
Valuation allowance	(2,115,268)	(3,951,208)
Federal net operating loss carryforwards	6,393,000	12,277,000
Federal research credit carryforwards	140,553	257,343
State net operating loss carryforwards	6,393,000	12,277,000
State research credit carryforwards	$ 140,553	$ 257,343
Domestic Tax Authority [Member]
Operating loss carryforwards, expiration date		Dec. 31, 2036
Research credit carryforwards, expiration date		Dec. 31, 2036
State and Local Jurisdiction [Member]
Operating loss carryforwards, expiration date		Dec. 31, 2031
Research credit carryforwards, expiration date		Dec. 31, 2032

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2019
Defined Contribution Plan (Textual)
Employees defer compensation, percentage		100.00%
Employee deferrals contributions, description		The Company has a 401(k) defined contribution plan (the “401K Plan”) for all employees over age 21. Employees can defer up to 100% of their compensation through payroll withholdings into the 401K Plan subject to federal law limits. The Company matches 100% of deferrals up to 3% of one’s contributions. The Company’s matching contributions to employee deferrals are discretionary. The Company may also make discretionary profit sharing contributions under the 401K Plan in the future, but it has not done so through September 30, 2019.
Employee contributions, vesting percentage		100.00%
Employee deferrals, vesting term		6 years
Contributions cost	$ 7,779	$ (4,359)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended			9 Months Ended	12 Months Ended
	Nov. 01, 2019	Oct. 23, 2019	Oct. 07, 2019	Sep. 30, 2018	Sep. 30, 2019
Subsequent Events (Textual)
Monthly rent					$ 47,630
Common Stock [Member]
Subsequent Events (Textual)
Issued and sold common stock				445,200
Subsequent Event [Member]
Subsequent Events (Textual)
Initial base rent			$ 6,410
Monthly rent			$ 7,076
Subscription agreement, description	The Company entered into a subscription agreement with certain accredited investors, pursuant to which the Company, in a private placement, agreed to issue and sell to the investors 13% convertible promissory notes (each, a "Paulson Note" and collectively, the "Paulson Notes") and warrants (each, a "Paulson Warrant" and collectively, the "Paulson Warrants") to purchase shares of the Company's common stock.
Principal amount	$ 3,234,800
Notes bear interest rate	13.00%
Warrant grants, description	(i) 0.5 multiplied by (ii) the principal amount of such subscriber's Paulson Notes divided by 1.87, with an exercise price per share equal to $1.87. As of the final closing on December 3, 2019, the Company issued Paulson Warrants exercisable for 864,913 shares of Common Stock in connection with all closings of the private placement. The Paulson Warrants are immediately exercisable and expire on November 1, 2022.
Subsequent Event [Member] | Private Placement [Member]
Subsequent Events (Textual)
Convertible notes offering, description	The private placement, Paulson Investment Company ("Paulson") will receive a cash commission equal to 12% of the gross proceeds from the sale of the Paulson Notes, and 10-year warrants to purchase an amount of Common Stock equal to 15% of the total amount of shares of Common Stock into which the Paulson Notes are convertible, at an exercise price equal to the offering price of the Company's securities in the next Qualified Financing.
Subsequent Event [Member] | Common Stock [Member]
Subsequent Events (Textual)
Issued and sold common stock		141,666
Share price		$ 1.80
Proceeds from issuance of common stock		$ 300,000
Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member]
Subsequent Events (Textual)
Issued and sold common stock		555,555
Proceeds from issuance of common stock		$ 1,000,000
Convertible notes offering, description		The Paulson Notes bear interest at a fixed rate of 13% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on May 1, 2020. If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the “Qualified Financing”), each subscriber shall have the option to convert the outstanding principal and accrued and unpaid interest of such subscriber’s Paulson Note (the “Outstanding Balance”) into the securities issued by the Company in such Qualified Financing in an amount equal to (i) the Outstanding Balance divided by (ii) the lower of 0.6 multiplied by (A) the actual per share price of securities issued by the Company in the Qualified Financing and (B) the ten day volume weighted average closing price of the common stock prior to the first closing of a Qualified Financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the maturity date, the Paulson Notes would become payable on demand as of the closing date of such transaction. Change of control means a merger or consolidation with another entity in which the Company’s stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company’s assets.